Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.45 |
| ▸ | NPC1 | O15118 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 1/20 | 0.45 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.41 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.41 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.41 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 2/20 | 0.40 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | PDK3 | Q15120 | 2/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9888570 | 1.00 | CYP1A2 (0.46) | CYP1A2MAPK1NPC1RAB9APTPN1 | |
| SCHEMBL30450959 | 1.00 | CYP1A2 (0.46) | CYP1A2MAPK1NPC1RAB9APTPN1 | |
| SCHEMBL997814 | 1.00 | CYP1A2 (0.46) | CYP1A2MAPK1NPC1RAB9APTPN1 | |
| SCHEMBL583794 | 0.87 | CYP1A2 (0.43) | CYP1A2MAPK1NPC1RAB9APTPN1 | |
| SCHEMBL1933910 | 0.85 | CYP1A2 (0.54) | CYP1A2PTPN1ALDH1A1TSHRCYP2C9 | |
| SCHEMBL30940437 | 0.83 | CYP1A2 (0.52) | CYP1A2PTPN1ALDH1A1TSHRCYP2C9 | |
| SCHEMBL404851 | 0.83 | MAPK1 (0.46) | MAPK1NPC1RAB9APTPN1ALDH1A1 | |
| SCHEMBL30031482 | 0.83 | KCNN4 (0.45) | MAPK1NPC1RAB9AALDH1A1CES1 | |
| SCHEMBL2398996 | 0.83 | MAPT (0.50) | CYP1A2MAPK1NPC1RAB9APTPN1 | |
| SCHEMBL4454875 | 0.83 | KCNN4 (0.45) | MAPK1NPC1RAB9AALDH1A1CES1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME LLC (US) | 2023-05-23 | — | — | US | disclosed |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | Integral Biosciences Privated Limited (IN) | 2022-11-17 | — | — | US | disclosed |
| WO-2022224166-A1 | COMPOUNDS AS LXR AGONISTS | INTEGRAL BIOSCIENCES PRIVATE LIMITED (IN) | 2022-10-27 | — | — | WO | disclosed |
| EP-3526203-B1 | N-ARYL AND N-HETEROARYL PIPERIDINE DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2021-09-22 | — | — | EP | disclosed |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | MERCK SHARP & DOHME CORP. (US) | 2021-03-30 | — | — | US | disclosed |
| EP-3383853-B1 | HOMOBISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR (LXR) BETA AGONISTS FOR TREATING E.G. ALZHEIMER'S DISEASE | MERCK SHARP & DOHME (US) | 2020-11-04 | — | — | EP | disclosed |
| EP-3373933-B1 | BISPIPERIDINYL DERIVATIVES AS LIVER X RECEPTOR BETA AGONISTS, COMPOSITIONS, AND THEIR USE | MERCK SHARP & DOHME (US) | 2020-08-26 | — | — | EP | disclosed |
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2020-08-25 | — | — | US | disclosed |
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | MERCK SHARP & DOHME CORP. (US) | 2020-08-25 | — | — | US | disclosed |
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK SHARP & DOHME CORP. | 2009-11-05 | — | — | US | disclosed |
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2009-04-02 | — | — | US | disclosed |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | MERCK SHARP & DOHME CORP. | 2008-06-12 | — | — | US | disclosed |
| WO-2008048540-A2 | 2-HYDROXY-2-PHENYL/THIOPHENYL PROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2008-04-24 | — | — | WO | disclosed |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2007-09-27 | — | — | US | disclosed |
| US-7268153-B2 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK & CO., INC. (US) | 2007-09-11 | — | — | US | disclosed |
| EP-1755572-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | Merck & Co., Inc. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005120477-A2 | N- (2-BENZYL) -2-PHENYLBUTANAMIDES AS ANDROGEN RECEPTOR MODULATORS | MERCK & CO., INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | MERCK SHARP & DOHME CORP. | 2005-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10752587-B2 | Homobispiperidinyl derivatives as liver X receptor beta agonists, compositions and their use | NR1H2, NR1H3, NR1H4 | CYP1A2 84/4885MAPK1 3200/4885NPC1 134/4885 |
| US-20090088458-A1 | N-(Pyridin-4-Yl)-2-Phenylbutanamides as Androgen Receptor Modulators | SHBG, AR, NR5A1 | CYP1A2 849/4885MAPK1 2147/4885NPC1 3234/4885 |
| US-20050277681-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | CYP1A2 800/4885MAPK1 2625/4885NPC1 2304/4885 |
| US-20090275515-A1 | 2-HYDROXY-2-PHENYLTHIOPHENYLPROPIONAMIDES AS ANDROGEN RECEPTOR MODULATORS | SHBG, AR, FSHR | CYP1A2 883/4885MAPK1 3437/4885NPC1 3697/4885 |
| US-20220363662-A1 | COMPOUNDS AS LXR AGONISTS | NR1H2, NR1H3, NR1H4 | CYP1A2 81/4885MAPK1 1066/4885NPC1 31/4885 |
| US-11655216-B2 | Aryl and heteroaryl ether derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | CYP1A2 26/4885MAPK1 2352/4885NPC1 117/4885 |
| US-20070225229-A1 | N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators | SHBG, AR, BRCA1 | CYP1A2 800/4885MAPK1 2625/4885NPC1 2304/4885 |
| US-10961215-B2 | N-aryl and N-heteroaryl piperidine derivatives as liver X receptor beta agonists, compositions, and their use | NR1H2, NR1H3, NR1H4 | CYP1A2 63/4885MAPK1 2652/4885NPC1 17/4885 |
| US-20080139630-A1 | N-(2-Benzyl)-2-Phenylbutanamides As Androgen Receptor Modulators | SHBG, AR, NR5A1 | CYP1A2 758/4885MAPK1 2573/4885NPC1 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.